iRhythm’s first quarter saw a mix of strong financial performance and a muted market response, as revenue and adjusted profits surpassed Wall Street expectations. The company attributed its results to sustained demand for its ZioMonitor and Zio AT cardiac monitoring products, as well as operational improvements that drove margin expansion. CEO Quentin Blackford highlighted “broad-based growth across cardiology, primary care, innovative channels, and international markets,” while also noting progress in automating manufacturing and integrating workflows with electronic health records.
Is now the time to buy IRTC? Find out in our full research report (it’s free for active Edge members).
iRhythm (IRTC) Q1 CY2026 Highlights:
- Revenue: $199.4 million vs analyst estimates of $194 million (25.7% year-on-year growth, 2.8% beat)
- Adjusted EPS: -$0.35 vs analyst estimates of -$0.64 (45.3% beat)
- Adjusted EBITDA: $14.1 million vs analyst estimates of $6.88 million (7.1% margin, significant beat)
- The company slightly lifted its revenue guidance for the full year to $880 million at the midpoint from $875 million
- Operating Margin: -8.1%, up from -20.5% in the same quarter last year
- Market Capitalization: $3.87 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From iRhythm’s Q1 Earnings Call
-
JPMorgan: asked about the apparent growth deceleration implied in the full-year guide. CFO Daniel Wilson explained the approach reflects caution early in the year and more difficult comparisons later, but noted momentum remains strong and upside is possible if trends persist.
-
BofA: inquired about EBITDA margin outperformance and the restrained full-year margin raise. Wilson attributed improvements to operational efficiencies and automation, reiterating that guidance remains conservative early in the year.
-
William Blair: questioned how learnings from long-standing innovative channel partners are being applied to new accounts. CEO Quentin Blackford said every partner piloting in 2025 is now active in 2026, with growing use cases and pipeline strength, especially as partners shift from symptomatic to asymptomatic populations.
-
Evercore ISI: asked about the Department of Justice inquiry and scope of information requested. Blackford clarified the investigation is focused on the Zio AT product line and covers activity primarily in the 2021–2022 period, with no recent requests for additional information.
-
R.W. Baird: asked whether the company is seeing any benefit from chart-derived diagnosis reconfirmations in its guidance. Blackford said no benefit was included in the outlook, but noted confirmatory diagnostics are a tailwind as partners increasingly use Zio for validated diagnoses.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will monitor (1) the FDA’s review outcome for iRhythm’s next-generation AI algorithm and Zio MCT device; (2) the pace of primary care adoption as a driver of volume growth; and (3) further reimbursement developments in international markets, particularly Japan. Progress in sleep diagnostics pilots and resolution of regulatory actions will also be important for tracking strategic execution.
iRhythm currently trades at $117.67, down from $129.16 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free).
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
